| Primary |
| Drug Use For Unknown Indication |
29.8% |
| Product Used For Unknown Indication |
13.2% |
| Bronchopneumopathy |
7.0% |
| Staphylococcal Infection |
7.0% |
| Urinary Tract Infection |
5.3% |
| Hyperpyrexia |
4.4% |
| Influenza |
4.4% |
| Bronchitis |
3.5% |
| Gastric Ulcer Helicobacter |
3.5% |
| Pyrexia |
3.5% |
| Bronchopneumonia |
2.6% |
| Pneumonia |
2.6% |
| Bacterial Infection |
1.8% |
| Cystitis |
1.8% |
| Diabetes Mellitus |
1.8% |
| Ill-defined Disorder |
1.8% |
| Oropharyngeal Gonococcal Infection |
1.8% |
| Post Procedural Infection |
1.8% |
| Prostatitis |
1.8% |
| Anaemia |
0.9% |
|
| Dyspnoea |
10.9% |
| Epilepsy |
8.7% |
| Nephrotic Syndrome |
8.7% |
| Urticaria |
6.5% |
| Ventricular Fibrillation |
6.5% |
| Dermatitis |
4.3% |
| Disorientation |
4.3% |
| Dyskinesia |
4.3% |
| Hepatitis |
4.3% |
| Hypoglycaemia |
4.3% |
| Intestinal Obstruction |
4.3% |
| Loss Of Consciousness |
4.3% |
| Malaise |
4.3% |
| Papilloedema |
4.3% |
| Purpura Non-thrombocytopenic |
4.3% |
| Rash Pruritic |
4.3% |
| Restlessness |
4.3% |
| Atrial Fibrillation |
2.2% |
| Bronchospasm |
2.2% |
| Death |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
24.8% |
| Product Used For Unknown Indication |
19.5% |
| Febrile Neutropenia |
7.5% |
| Asthma |
5.3% |
| Bronchopneumopathy |
4.5% |
| Interstitial Lung Disease |
4.5% |
| Pneumonitis |
4.5% |
| Bronchopneumonia |
3.8% |
| Atrial Fibrillation |
3.0% |
| Bronchitis |
3.0% |
| Pleural Thickening |
3.0% |
| Atypical Mycobacterial Infection |
2.3% |
| Pneumonia |
2.3% |
| Post Procedural Infection |
2.3% |
| Pyrexia |
2.3% |
| Antibiotic Prophylaxis |
1.5% |
| Cough |
1.5% |
| Decubitus Ulcer |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Hyperpyrexia |
1.5% |
|
| Purpura |
10.8% |
| Rash |
10.8% |
| International Normalised Ratio Increased |
8.1% |
| Tremor |
8.1% |
| Ventricular Fibrillation |
8.1% |
| Epilepsy |
5.4% |
| Hepatitis Acute |
5.4% |
| Pneumonia |
5.4% |
| Skin Reaction |
5.4% |
| Tachycardia |
5.4% |
| Fungal Infection |
2.7% |
| Hypersensitivity Vasculitis |
2.7% |
| Infusion Site Erythema |
2.7% |
| Liver Disorder |
2.7% |
| Melaena |
2.7% |
| Nephrotic Syndrome |
2.7% |
| Pruritus |
2.7% |
| Self Injurious Behaviour |
2.7% |
| Sensory Disturbance |
2.7% |
| Transaminases Increased |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
34.2% |
| Product Used For Unknown Indication |
13.9% |
| Diffuse Large B-cell Lymphoma |
11.4% |
| Non-hodgkin's Lymphoma |
6.5% |
| Acute Myeloid Leukaemia |
4.6% |
| Prophylaxis |
4.6% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Recurrent |
3.2% |
| High Grade B-cell Lymphoma Burkitt-like Lymphoma Recurrent |
3.2% |
| Multiple Myeloma |
2.1% |
| Atrial Fibrillation |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Infection Prophylaxis |
1.7% |
| Non-small Cell Lung Cancer |
1.7% |
| Plasma Cell Myeloma |
1.5% |
| Antibiotic Prophylaxis |
1.3% |
| Decreased Appetite |
1.3% |
| Dehydration |
1.3% |
| Hyperuricaemia |
1.3% |
| Meningitis Listeria |
1.3% |
| Neutropenia |
1.3% |
|
| Neutropenia |
10.9% |
| Polyneuropathy |
10.9% |
| Septic Shock |
9.1% |
| Hepatitis Cholestatic |
7.3% |
| Stent Placement |
7.3% |
| Hypotension |
5.5% |
| Stomatitis |
5.5% |
| Toxic Skin Eruption |
5.5% |
| Gastrointestinal Perforation |
3.6% |
| Haemoglobin Decreased |
3.6% |
| Hepatitis B Dna Increased |
3.6% |
| Hypoglycaemia |
3.6% |
| Peripheral Sensory Neuropathy |
3.6% |
| Pseudomonal Sepsis |
3.6% |
| Rash Morbilliform |
3.6% |
| Stevens-johnson Syndrome |
3.6% |
| Ventricular Arrhythmia |
3.6% |
| Anuria |
1.8% |
| Cerebral Ischaemia |
1.8% |
| Cholecystectomy |
1.8% |
|
| Interacting |
| Pleural Effusion |
50.0% |
| Atrial Fibrillation |
25.0% |
| Urinary Tract Infection Fungal |
25.0% |
|
|
